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Summary 
Background 
Depression in schizophrenia predicts poor outcomes, including suicide, yet the 
effectiveness of antidepressants for its treatment remains uncertain. The aim of this 
study was to synthesise the evidence of the effectiveness of antidepressants for the 
treatment of depression in schizophrenia.  
Methods 
Following Prisma guidelines, multiple databases were searched for trials 
investigating the effectiveness of antidepressant treatment for people with 
schizophrenia and depression. Inclusion criteria included participants aged over 18 
years with schizophrenia or related psychosis with a depressive episode. Papers 
were quality assessed used the Cochrane risk bias tool. Data was extracted with 
meta-analyses performed for risk difference and standardised mean difference of all 
antidepressants, antidepressant class and individual antidepressant where sufficient 
studies allowed.  
Results 
26 moderate to low quality trials met inclusion criteria. In meta-analysis a significant 
risk difference was found in favour of antidepressant treatment, with a number 
needed to treat of 5 (95% CI 4-9). Studies using tools specifically designed to assess 
depression in schizophrenia showed a larger effect size. However, after sensitivity 
analysis standardised mean difference of all antidepressants did not show a 
statistically significant improvement in depression score at end-point, neither did any 
individual antidepressant class.  
Conclusion 
Antidepressants may be effective for the treatment of depression in schizophrenia, 
however the evidence is mixed and conclusions must be qualified by the small 
number of low or moderate quality studies. Further sufficiently powered, high quality 
studies are needed.  
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1. Introduction 
Depression is now widely recognised as a common, discrete syndrome within 
schizophrenia, with prevalence of over 50% (1, 2).  Depression in schizophrenia is 
associated with more frequent psychotic episodes (3), increased duration of illness 
(4), substance abuse (5), poor quality of life and suicide (6, 7).  Depression in 
schizophrenia also has impact on systems outside of the individual and health care 
burden with greater use of the mental health services and criminal justice system (1). 
Despite the clear need for effective management of depression in schizophrenia, 
there is a lack of specific guidance. The British Association for Psychopharmacology 
guidelines on the treatment of schizophrenia conclude that “the potential benefit of 
adjunctive antidepressants for comorbid depressive symptoms has not received the 
attention it might seem to warrant, given how often depression occurs”(8). The 
National Institute for Health and Care Excellence (NICE) guidelines for the treatment 
schizophrenia and first-episode psychosis emphasise that it is important to “routinely 
monitor for other coexisting conditions, including depression…. particularly in the 
early phases”, but make no specific recommendation for the treatment of depression 
occurring in schizophrenia (9). Clinicians presently are left to personal experience in 
treatment decisions, and thus prescribing varies considerably (10).  
A 2002 meta-analysis identified 11 appropriate trials in this field; these studies had 
multiple methodological flaws including small sample size, absent reporting of 
allocation concealment and few using an intention to treat analysis(4). The majority 
of included studies assessed effect of tricyclic antidepressants, which in the modern 
age would not be first line therapy for depression. This review concluded that there 
may be some benefit of co-prescribing antidepressants in schizophrenia, however a 
fairer conclusion would be evidence at the time was “unproven”.  
Additional medication, and subsequent polypharmacy, is not without risk in severe 
mental illness, where patients already have high side effect burden and poor 
physical health (11). Concomitant use of antidepressants with antipsychotics 
potentially leads to cardiac effects, and require additional monitoring including for 
prolongation of QTc (12). However, Helfer and colleagues recently reported on the 
safety and efficacy of antidepressants added to antipsychotics in the treatment of 
schizophrenia. They conclude that this is a low risk combination that may produce 
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some beneficial effects (13). Their review had a broad focus, including all papers 
where antidepressants were co-prescribed, and did not specifically aim to investigate 
the effect of antidepressants for the treatment of comorbid depression in 
schizophrenia. Thus the benefit of additional antidepressant use for the treatment of 
depression in schizophrenia still needs a more robust evidence base. 
In summary, the current lack of evidence exacerbates the challenge of providing 
optimal pharmacotherapy for individuals with schizophrenia who are depressed. This 
systematic review and meta-analysis aimed to synthesise evidence and estimate the 
aggregate effectiveness of antidepressants for the treatment of depression in people 
with schizophrenia. We also explore whether any particular antidepressant class or 
individual antidepressant had stronger evidence of effect. 
 
2. Methods 
Search strategy and selection criteria 
This meta-analysis adhered to PRISMA guidelines and followed a predetermined 
published protocol. In this paper, we report results from our primary outcome as 
included in the published protocol(14): response to antidepressant treatment 
(responder/non responder) and improvement in depression score using a 
standardised rating scale. 
Inclusion Criteria were as follows: 
Participants: Human subjects aged 18 years or older with schizophrenia or related 
psychosis (e.g. schizoaffective disorder and psychotic disorder not otherwise 
specified) with a depressive episode as assessed using a standardised rating scale 
or clinical interview.  
Intervention: Antidepressant (any class) versus usual care or placebo.  
Types of Outcome: 1) Response to antidepressant therapy using dichotomous 
outcomes (responder/ non responder). 2) Continuous outcomes, as measured by 
change on standardised depression rating scales.  
Types of Studies:  All randomised controlled trials or quasi-experimental studies.  
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Exclusion criteria were as follows: 
Observational or qualitative studies; studies including participants with a primary 
diagnosis of organic brain disorder or bipolar disorder, on the basis that depression 
experienced in these disorders would have a very different aetiology and would be 
managed differently to the focus of this review. Therapeutic agents with only 
theoretical antidepressant property not approved for the treatment of depression, 
review articles and studies not published in English were also excluded. 
MEDLINE, EMBASE, Psycinfo, CINAHL and the Cochrane Library were searched 
from inception to the final update in March 2017. Combination of keywords and index 
terms were used to describe the population, condition and intervention and included: 
[«Schizophreni*» OR «Schizoaffective»] OR [«Psychosis» OR «Psychoses»] AND 
[«Depress*» OR «Depressive disorder»] AND [«Antidepressant*» OR 
«Antidepressive*» OR «Tricyclic*» OR «Serotonin reuptake inhibitor» OR « 
Monoamine oxidase inhibitors»] (see published protocol). Information regarding on-
going trials was obtained by searching the International Clinical Trials Registry and 
ClinicalTrials.gov. Key authors were contacted to identify whether any further trials 
could be identified and seek additional data from studies as required.  
Data Analysis 
Data was extracted using the Cochrane data collection form to capture: design, 
inclusion/exclusion criteria, population, details of intervention and control conditions, 
attrition rates, outcomes and times of measurement, concurrent medications and 
results. Publications pertaining to the same research group and examining the same 
antidepressant were checked for data overlap. Two reviewers (AG and RU) 
independently assessed the methodological quality of each study using the 
Cochrane risk of bias tool without blinding to authorship or source.  
The primary outcomes were 1) Response to antidepressant therapy and 2) 
Improvement in follow-up depression score. Means and standard deviation of follow-
up scores were extracted from reports or by conversion of the standard error. The 
final assessment of outcomes was used when studies reported multiple follow-up 
times. To summarise effect of trials, risk difference (RD) was calculated for binary 
outcomes and standardised mean difference (SMD) for continuous outcomes. A 
fixed-effects analysis was undertaken in the absence of heterogeneity (I2 <50%).  
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Sub group meta-analyses were also carried out according to a) length of follow up b) 
antidepressant class and c) individual antidepressant where possible. Individual 
subgroup analysis were conducted, rather than meta-regression, as these were 
specific pre identified questions with less than ten identified studies in each group, in 
keeping with Cochrane guidance (15). As our retrieval of published papers allowed, 
we also included a sub-analysis on studies using the Calgary Depression Scale for 
Schizophrenia (CDSS), which is established as having greater specificity for rating 
depression in schizophrenia (16).  
One of the trials evaluated two antidepressants, to avoid counting the same 
individuals twice, the sample size in the placebo group was halved in both 
comparisons. Statistical analyses used Revman 5.3. 
3. Results 
A total of 1416 non-duplicated articles were identified. Following application of 
inclusion criteria, 26 trials were included in the review (see Figure 1 and 
supplementary table 1). Of the 26 trials, 4 were identified through citation list 
inspection of included sources. The main reasons for exclusion of full text articles 
were publications reviewing existing literature (n39), populations with no depression 
at baseline, those not investigating schizophrenia or related disorder (n14), and 
observational trials lacking a control (n20). 
 
Characteristics of Included Studies  
Participants of 19 studies included individuals with a core diagnosis of schizophrenia, 
1 with a schizoaffective disorder, 6 with mixed schizophrenia and schizoaffective 
disorder. Most trials used ICD-10(17), DSM II-IV(18) or RDC(19) definitions of 
schizophrenia. However, 2 studies stated only that a diagnosis of schizophrenia had 
been made (20, 21) and 2 trials used positive Feighner or Schneiderian symptoms 
(22, 23).  
 
Outcome measures: 15 studies evaluated depression as their primary outcome. 8 
focused on treatment of negative symptoms or cognitive functioning but included 
depressed subjects and reported depression specific outcome measures. 
Depression inclusion criteria varied; 8 studies incorporated a Hamilton Depression 
 7 
Rating Scale (HAM-D) cut off which ranged from greater than 8 to 18, 5 studies 
stated participants must have met DSM or RDC diagnoses for a major depressive 
episode, 3 studies used the Becks Depression Inventory (BDI), 2 used Raskin 
Depression Scale and 1 study used a Calgary Score for Depression in 
Schizophrenia (CDSS) with cut off of 5. 1 study stated only that ‘clinically significant 
subsyndromal depressive symptoms’ were present (24).  
  
Response: The definition of response from depression varied between studies. We 
defined our outcome of ‘response’ directly according to those of the original authors;  
2 studies used a 50% or greater reduction in standardised depression measure 
scores (25, 26) and 6 reported response on a Clinical Global Impression or 
equivalent scale (22, 23, 27-30).  
All studies also reported an evaluation of change in depression score, HAM-D, BDI, 
and CDSS.  
Phase of Illness: 6 studies did not report the phase of psychotic illness. 18 described 
their participants as having chronic illness and 2 studies included populations with 
early psychosis (31, 32), however both of these trials contained populations of both 
first episode and recurrently ill participants.   
Duration of follow up: 12 studies were 6 weeks in length and 15 were 8 or more 
weeks.  
Antidepressant: The most frequent antidepressant class examined was selective 
serotonin reuptake inhibitors (SSRIs) followed by tricyclic antidepressants (TCAs). 
Placebo was the comparator in all except 2 trials (31, 33) where antipsychotics alone 
were the control.  
See supplementary table 1 for full details.  
 
Quality Assessment  
Less than half of studies had a sample size of over 50 participants and only 4 trials 
indicated an a priori sample size calculation (24, 25, 34, 35). All studies specified 
eligibility criteria and conducted randomisation. 8 trials gave detail on randomisation 
procedures and 4 described the method of allocation concealment (34-37). The 
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primary outcome was explicitly stated prior to research commencing in 13 studies. 3 
trials were open-label (31, 33, 37) and 4 trials explicitly detailed blinding of assessors 
(25, 33, 35, 38). Analysis was carried out on an intention to treat basis in 11 studies. 
To summarise, 19 out of the 26 included articles would not meet current standards 
for reporting randomised controlled trials (See supplementary figure 1 for full details). 
Quantitative Synthesis   
i. Response to antidepressant: Categorical Outcome  
Binary data (responder/non responder) at end point follow up was reported by 8 
included studies. In meta-analysis of these studies homogeneity was found  (2 = 
7·09 df=7 p=0·42, n=515). Meta-analysis demonstrated a significant benefit of 
antidepressants with a small summary risk difference -0·19 (95% CI -0·27 to -0·11), 
(I2 1%), and corresponding number needed to treat (NNT) of 5 (95% CI 4 to 9) (see 
Figure 2).  
 
Subgroup analysis indicated no significant difference between studies that combined 
schizophrenia and schizoaffective disorder in their population compared to 
populations with a core diagnosis of schizophrenia (see supplementary figure 2).  
 
ii. Improvement in in follow-up depression score  
a. All Antidepressants 
Random effects meta-analysis of 17 studies reporting end point depression score 
showed a significant improvement in favour of treatment; SMD -0·24 (95% CI -0·48 
to 0·01). However, within a sensitivity analysis, with removal of one very small study 
with large effect size (Kasckow 2001) this became non-significant: SMD -0·20 (95% 
CI -0·40 to 0·02). See supplementary figure 3. 
 
 
b. Length of Follow up 
Subgroup analysis comparing trials with long term (>8 weeks) and short term (<6 
weeks) intervention showed this length of treatment did not affect the outcome. See 
supplementary figure 4. 
 
c. Antidepressant Class 
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Meta-analysis of 8 studies investigating the efficacy of SSRI on the improvement of 
depression score using the HAM-D did not reveal a significant difference; SMD -0·11 
(95% CI -0·48 to 0·27). See supplementary figure 5. The format and lack of 
continuous data given by studies investigating TCAs prevented meta-analysis of this 
class.  Analysis of all other antidepressants (e.g. SNRI, receptor blockers) which 
reported outcome by change in depression score showed no significant 
improvement; SMD -0·16 (95% CI -0·63 to 0·32).  See supplementary figure 6. 
 
d. Individual Antidepressants  
Citalopram was the only individual antidepressant with a sufficient number of trials to 
combine in meta-analysis. All 4 studies (n=324) measured endpoint depressive 
symptoms using the HAM-D. However there was significant heterogeneity (2 = 
15·23 df=3, p=0·002). Thus, although some studies demonstrate a significant 
difference, a random-effects model showed no significant effect (see Figure 3).  
 
e. Trials Reporting Depression using the Calgary Depression scale for 
Schizophrenia (CDSS) 
Trials reporting results using the CDSS as a continuous outcome (n= 331) 
demonstrated antidepressant therapy was statistically superior to placebo, with 
moderate effect; SMD -0·47 (95% CI -0·92 to -0·02). See Figure 4.  
 
Publication Bias  
Funnel plot did not reveal any indication of publication bias. Supplementary figure 7. 
 
4. Discussion 
This systematic review and meta-analysis of studies produced some evidence in 
favour of antidepressant treatment for depression in schizophrenia. Response, as 
defined by authors as a 50% reduction in depression score or clinically ‘not 
depressed’,  was significantly more likely when this depression was treated with an 
antidepressant. In studies that reporting endpoint using a measure specifically 
designed to assess depression in schizophrenia (the CDSS) there was a larger 
effect size of improvement. This suggests that efficacy for the treatment of 
depression may be larger than appears using broader assessment tools. Significant 
improvement was found in depression scores for all antidepressants, however this 
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result did not survive sensitivity analysis. Building on previous evidence, Whitehead 
in 2002 reported just one trial investigating an selective serotonin reuptake inhibitor 
(4), whereas in this present review the class formed the majority of studies. While 
non-significant summary risk differences were found for selective serotonin reuptake 
inhibitors as a class, an important contribution may be possible with citalopram; 
however, with significant heterogeneity and random effects modelling this result was 
also not statistically significant.  
Over and above evidence from Helfer and colleagues (13), who reviewed the impact 
of antidepressants prescribed for many reasons in schizophrenia, we were able to 
demonstrate the potential effectiveness of antidepressants when targeting the 
treatment of depression.  However, the evidence is not strong or conclusive; 
although a major influence for this is size and quality of trials available, other factors 
may be contributing to the weaker signal of efficacy detected. We have previously 
investigated the aetiology and phenomenology of depression in schizophrenia; and 
reported on significant pathways including the increased role of shame, anhedonia 
and hopelessness (39, 40). It is possible that depression in schizophrenia is 
qualitatively different to unipolar depression, and more specific tailored treatments 
are needed. Also, individual SSRI’s have differing additional properties, with some 
suggestion of an anti-inflammatory effect of citalopram which may be pertinent in 
depression seen in the context of schizophrenia (41). Further studies should explore 
these effects in the context of schizophrenia (12). 
However, recent reports do emphasise the safety of antidepressants in 
schizophrenia, including the use in combination with antipsychotics (13). Thus, 
clinical recommendations may wish to consider antidepressant medication for 
patients with depression and schizophrenia, although conclusions should be 
tempered by the moderate to low quality of studies available. Our findings do give an 
increase in the strength of evidence from previous literature that demonstrated mixed 
or weak effectiveness of antidepressants for depression in schizophrenia (4). Our 
analysis of trials reporting respose to antidepressant therapy demonstrates a number 
needed to treat (NNT) of five, which is equivalent to the NNT of antidepressant 
medications used for the treatment of depression (in the absence of schizophrenia),  
documented to be between seven and nine (42).  
Depression adds to the extensive burden of schizophrenia and its management is 
crucial to recovery (1). Improvement in depression status may lead to better long-
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term functional outcomes such as medication adherence, service utilisation, 
substance misuse, suicide attempts, and quality of life (1, 43). In April 2015 the first 
NHS access and waiting time standards in mental health services came into effect, 
and considerable investment is to focus on the treatment of first episode psychosis 
(44). Depression is common in first episode psychosis and it is both timely and 
essential that the evidence base around which treatments are effective and the 
extent of their effectiveness is robust. Our current findings further extend prior 
research by demonstrating a moderate effect size in favour of antidepressants over 
placebo, with effect sizes comparable to that found in meta-analysis of Cognitive 
Behavioural Therapy for psychosis (CBTp) (45). NICE continues to recommend that 
CBTp should be offered to all patients with schizophrenia and psychosis (46). It is 
therefore reasonable to assume our novel findings should similarly influence clinical 
guidelines.  
A lack of rigorous reporting of adverse outcomes in included trials in this review 
prevented calculation of number needed to harm and caution must be taken when 
recommending pharmacological interventions and the avoidance of unnecessary 
polypharmacy. In particular, the Medicines and Health Products Regulatory Authority 
issued guidance against the use of citalopram with medication that can also prolong 
QTc interval and lead to potential arrhythmias (47). However evidence has 
demonstrated this combination can be used without excess mortality and, in practice, 
antidepressants and antipsychotics are commonly prescribed together without 
incident (48). Likewise, psychosocial interventions are also not without their own 
potential adverse effects (49) yet often escape the close scrutiny that drug 
interventions are subject to, with detrimental effects unreported (50, 51). Thus on the 
whole, our results suggest antidepressant medication should be considered, whilst 
also accepting that further high quality robust studies are needed to give definitive 
guidance. 
 
Limitations 
The primary focus of seven studies was not the treatment of depression and this 
contributed to the heterogeneity of results. Some trials lacked clear depressive 
inclusion criteria and participants were recruited in different phases of illness, with 
the majority of trials evaluating antidepressants in chronic illness. Only two studies 
investigated antidepressants in early psychosis and both mixed these participants 
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with recurrently ill patients; this was disappointing given the significant evidence that 
depression is most prevalent in early years of illness and when risk of suicide is 
highest (52, 53). Studies did not report on any concurrent psychological or family 
based treatments, and it is possible if present these added further confounding 
factors. It should also be noted that even evidence for a significant response to 
treatment is not equivalent to evidence of recovery, would require studies to 
measure many factors in addition to change on a depression scale or objective 
clinical response. Finally, trials were disparate in outcome reporting. Most frequently 
depressive symptoms were evaluated using the HAM-D which is not designed to 
distinguish depressive from negative and extrapyramidal symptoms.  
 
Conclusion and Clinical Recommendation 
This systematic review and meta-analysis demonstrates qualified evidence that 
antidepressants may be effective in treating depression in people with schizophrenia. 
Future research should consider the methodological limitations of current published 
findings and above recommendations to ensure rigorous and conclusive results. 
Large-scale randomised controlled trials should prioritise the appropriate 
measurement of depressive symptoms in schizophrenia, include reporting of adverse 
outcomes and use an adequate method of randomisation, allocation concealment 
and have specific depression inclusion criteria. However, clinical guidelines should 
focus on the best evidence available to give treatment advice for this pressing area 
of clinical need. Current evidence suggests that it is possible that antidepressant 
medication is effective for the treatment of depression in schizophrenia, and 
clinicians would be justified in discussing an individual therapeutic trial with their 
patients. 
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Figure 1: PRISMA Flow Chart 
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Figure 2: Forest plot of response to antidepressant  
 
 
 
 
Figure 3: Forest plots of mean differences for citalopram in HAM-D score at follow up 
using a random effects model.  
 
 
 
Figure 4: Forest plot of mean differences in CDSS score at follow up using a random 
effects model. 
 
 
 
 
 
 
